Rate this article:

Article of the Week: Sentinel node biopsy for prostate cancer: report from a consensus panel meeting


Every Week the Editor-in-Chief selects an Article of the Week from the current issue of BJUI. The abstract is reproduced below and you can click on the button to read the full article, which is freely available to all readers for at least 30 days from the time of this post.

In addition to the article itself, there is an accompanying editorial written by a prominent member of the urological community. This blog is intended to provoke comment and discussion and we invite you to use the comment tools at the bottom of each post to join the conversation.

If you only have time to read one article this week, it should be this one.

Sentinel node biopsy for prostate cancer: report from a consensus panel meeting

Henk G. van der Poel* , Esther M. Wit*, Cenk Acar, Nynke S. van den Berg,Fijs W. B. van Leeuwen, Renato A. Valdes Olmos, Alexander Winter§,Friedhelm Wawroschek§, Fredrik Liedberg**, Steven Maclennan††and Thomas Lam†† On behalf of the Sentinel Node Prostate Cancer Consensus Panel Group members 


*Department of Urology, Netherlands Cancer Institute, Amsterdam, The Netherlands, Department of Urology, Eryaman Hospital, Ankara, Turkey, Department of Radiology, University of Leiden Medical Centre, Leiden, The Netherlands, §Klinikum Oldenburg, School of Medicine and Health Sciences, University Hospital for Urology, Oldenburg, Germany, Department of Urology, Skane University Hospital, Malmo, **Department of Translational Medicine Lund University, Lund, Sweden, and ††Academic Urology Unit, University of Aberdeen, Aberdeen, UK




To explore the evidence and knowledge gaps in sentinel node biopsy (SNB) in prostate cancer through a consensus panel of experts.


A two-round Delphi survey among experts was followed by a consensus panel meeting of 16 experts in February 2016. Agreement voting was performed using the research and development project/University of California, Los Angeles Appropriateness Methodology on 150 statements in nine domains. The disagreement index based on the interpercentile range, adjusted for symmetry score, was used to assess consensus and non-consensus among panel members.



Consensus was obtained on 91 of 150 statements (61%). The main outcomes were: (1) the results from an extended lymph node dissection (eLND) are still considered the ‘gold standard’, and sentinel node (SN) detection should be combined with eLND, at least in patients with intermediate- and high-risk prostate cancer; (2) the role of SN detection in low-risk prostate cancer is unclear; and (3) future studies should contain oncological endpoints as number of positive nodes outside the eLND template, false-negative and false-positive SN procedures, and recurrence-free survival. A high rate of consensus was obtained regarding outcome measures of future clinical trials on SNB (89%). Consensus on tracer technology was only obtained in 47% of statements, reflecting a need for further research and standardization in this area. The low-level evidence in the available literature and the composition of mainly SNB users in the panel constitute the major limitations of the study.


Consensus on a majority of elementary statements on SN detection in prostate cancer was obtained.; therefore, the results from this consensus report will provide a basis for the design of further studies in the field. A group of experts identified evidence and knowledge gaps on SN detection in prostate cancer and its application in daily practice. Information from the consensus statements can be used to direct further studies.

Read more articles of the week

Please note that all submitted comments will be reviewed by the BJUI Web Team before they are considered for publishing on the site. Comments may take up to 48 hours to go live. If you have made a comment which has not appeared live after this time and you wish to discuss this matter further, please contact us.